Platinum complexes chemotherapeutic agents

The unchanged incidence of nephrotoxicity with inorganic platinum compounds stresses the need for ongoing research to identify platinum complexes with potent antitumor activity that are less nephrotoxic. Until this goal is achieved, it seems prudent to explore combinations of platinum with chemotherapeutic agents that are not associated with significant nephrotoxidly plus avoiding other concomitant nephrotoxic insults, especially volume depletion. 

Because of the discovery that platinum(II) complexes are useful chemotherapeutic agents, recent interest has centered on the coordination of platinum(II) to biologically interesting ligands. This work is covered in Chapter 62.2 by Lock. In this chapter only very brief mention will be made of the ligands which have been studied for their coordination to platinum, and, because of space limitation and duplication, no details of the complexes will be covered. 

Cisplatin [SIS pla tin] is a member of the platinum coordination complex class of anticancer drugs. Because of cisplatin s severe toxicity, carboplatin [KAR bow pla tin] was developed. The therapeutic effectiveness of the two drugs is similar but their pharmacokinetics, patterns of distribution and dose-limiting toxicities differ. Cisplatin has synergistic cytotoxicity with radiation and other chemotherapeutic agents. 

B. Brown, A. R. Khokhar, M. P. Hacker, J. J. MacCormack, and R. A. Newman, Synthesis and Biological Studies of a New Class of Antitumor Platinum Complexes, in S. J. Lippard, ed.. Platinum, Gold, and Other Metal Chemotherapeutic Agents, American Chemical Society, Washington, DC, 1983, pp. 265-277. 

Anti-tumour chemotherapeutic agents, doxorubicin and (dach)platinum(II) complex (where dach is trans-1,2-diaminocyclohexane) were introdueed into poly(organophosphazene) using L-glutamic acid as a spacer. The in vivo anti-tumour activity increased with increasing (dach)platinum(II) content, the conjugate containing 12.3 mol% of doxorubicin and 47.6 mol%... 

M. J. Clarke Ruthenium Anticancer Agents and Relevant Reactions of Ruthenium-Purine Complexes (Platinum, Gold and Other Metal Chemotherapeutic Agents v. 209, Ed. S. J. Lippard), p. 335. ACS, Washington (1983). 

---